These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31884389)

  • 1. Evaluation the potential of recombinant anti-CD3 nanobody on immunomodulatory function.
    Moradi-Kalbolandi S; Sharifi-K A; Darvishi B; Majidzadeh-A K; Jalili N; Sadeghi S; Mosayebzadeh M; Sanati H; Salehi M; Farahmand L
    Mol Immunol; 2020 Feb; 118():174-181. PubMed ID: 31884389
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Khatibi AS; Roodbari NH; Majidzade-A K; Yaghmaei P; Farahmand L
    Immunotherapy; 2019 Dec; 11(18):1555-1567. PubMed ID: 31865872
    [No Abstract]   [Full Text] [Related]  

  • 3. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
    Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
    J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice.
    Forster K; Goethel A; Chan CW; Zanello G; Streutker C; Croitoru K
    Gastroenterology; 2012 Nov; 143(5):1298-1307. PubMed ID: 22819863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors.
    Merikhian P; Darvishi B; Jalili N; Esmailinejad MR; Khatibi AS; Kalbolandi SM; Salehi M; Mosayebzadeh M; Barough MS; Majidzadeh-A K; Yadegari F; Rahbarizadeh F; Farahmand L
    Mol Oncol; 2022 Jan; 16(2):485-507. PubMed ID: 34694686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Separation of multiple genes controlling the T-cell proliferative response to IL-2 and anti-CD3 using recombinant congenic strains.
    Lipoldová M; Kosarová M; Zajícová A; Holán V; Hart AA; Krulová M; Demant P
    Immunogenetics; 1995; 41(5):301-11. PubMed ID: 7721352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
    Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
    Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
    Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
    MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
    Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
    J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy.
    Plain KM; Chen J; Merten S; He XY; Hall BM
    Transplantation; 1999 Feb; 67(4):605-13. PubMed ID: 10071035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation.
    Kusmartsev SA; Li Y; Chen SH
    J Immunol; 2000 Jul; 165(2):779-85. PubMed ID: 10878351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
    Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
    J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of T lymphocytes against EGF-receptor+ tumor cells by bispecific monoclonal antibodies: requirement of CD3 molecule cross-linking for T-cell activation.
    Ferrini S; Cambiaggi A; Sforzini S; Marciano S; Canevari S; Mezzanzanica D; Colnaghi MI; Grossi CE; Moretta L
    Int J Cancer; 1993 Dec; 55(6):931-7. PubMed ID: 8253530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory effect of water extract of cinnamon on anti-CD3-induced cytokine responses and p38, JNK, ERK1/2, and STAT4 activation.
    Lee BJ; Kim YJ; Cho DH; Sohn NW; Kang H
    Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):714-22. PubMed ID: 22053946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
    Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4 dependence of activation threshold and TCR signalling in mouse T lymphocytes.
    Feito MJ; Ballester S; Díez-Orejas R; Ojeda G; Criado G; Portolés P; Rojo JM
    Scand J Immunol; 1997 Feb; 45(2):166-74. PubMed ID: 9042429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cascading, interrelated roles of interleukin-1, interleukin-2, and interleukin-6 in murine anti-CD3-driven T cell proliferation.
    Pankewycz OG; Yui M; Kelley VE; Strom TB
    Clin Immunol Immunopathol; 1990 Apr; 55(1):67-85. PubMed ID: 2137741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial.
    Lum LG; LeFever AV; Treisman JS; Garlie NK; Hanson JP
    J Immunother; 2001; 24(5):408-19. PubMed ID: 11696696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects.
    Chavin KD; Qin L; Lin J; Kaplan AJ; Bromberg JS
    Transplantation; 1993 Apr; 55(4):901-8. PubMed ID: 8097344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.